The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients
Open accessAbstract
Alemtuzumab depletes malignant T cells but spares skin resident effector memory T cells, treating L-CTCL without increased risk of infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both CD8+ and CD4+ Trm have been identified in the human skin, lung, intestines, salivary glands, bone marrow, brain, spleen, tonsils, and lymph nodes [241, 244, 246, 253-259].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [246]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“They have been defined as independent populations by tissue retention in parabiosis experiments [239, 240], by distinguishing transcriptional profiles [230, 241-245], by exclusive Ag receptor repertoires and specificities [243, 244, 246], and by exclusive persistence in transplanted tissues [247, 248].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [246]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
Sallusto, F., Lenig, D., Förster, R., Lipp, M., & Lanzavecchia, A. (1999) · Nature · doi:10.1038/44385 · Cited by 5,846 · cited 2×
“TEM and TCM are two distinct subsets of memory T cells (9).”
BackgroundWHO-EORTC classification for cutaneous lymphomas
Willemze, R. (2005) · Blood · doi:10.1182/blood-2004-09-3502 · Cited by 3,803
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. P. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,565
Gebhardt, T., Wakim, L. M., Eidsmo, L., Reading, P. C., Heath, W. R., & Carbone, F. R. (2009) · Nature Immunology · doi:10.1038/ni.1718 · Cited by 1,157
The Vast Majority of CLA+ T Cells Are Resident in Normal Skin
Clark, R. A., Chong, B., Mirchandani, N., Brinster, N. K., Yamanaka, K.-I., Dowgiert, R. K., & Kupper, T. S. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.7.4431 · Cited by 796
Self-citationNaive and memory T cells show distinct pathways of lymphocyte recirculation.
Mackay, C. R., Marston, W. L., & Dudler, L. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.171.3.801 · Cited by 787
Long-term Outcome of 525 Patients With Mycosis Fungoides and Sézary Syndrome
Kim, Y. H., Liu, H. L., Mraz‐Gernhard, S., Varghese, A., & Hoppe, R. T. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.7.857 · Cited by 652
Campbell, J. J., Clark, R. A., Watanabe, R., & Kupper, T. S. (2010) · Blood · doi:10.1182/blood-2009-11-251926 · Cited by 519
Self-citationThe window of therapeutic opportunity in multiple sclerosis
Coles, A. J., Cox, A., Page, E. L., Jones, J., Trip, S. A., Deans, J., Seaman, S. R., Miller, D. H., Hale, G., Waldmann, H., et al. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0934-5 · Cited by 506
Motzer, R. J., Agarwal, N., Beard, C. J., Bolger, G. B., Boston, B., Carducci, M. A., Choueiri, T. K., Figlin, R. A., Fishman, M., Hancock, S., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0043 · Cited by 471
Migration, maintenance and recall of memory T cells in peripheral tissues
Woodland, D. L., & Kohlmeier, J. E. (2009) · Nature reviews. Immunology · doi:10.1038/nri2496 · Cited by 433
Lundin, J., Hagberg, H., Repp, R., Cavallin-Ståhl, E. K., Fredén, S., Juliusson, G., Rosenblad, E., Tjønnfjord, G. E., Wiklund, T. A., & Österborg, A. (2003) · Blood · doi:10.1182/blood-2002-09-2802 · Cited by 390
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model
Hu, Y., Turner, M. J., Shields, J. D., Gale, M. S., Hutto, E. H., Roberts, B., Siders, W., & Kaplan, J. M. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03115.x · Cited by 336
Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Byrd, J. C., Czuczman, M. S., Fayad, L., Forero, A., Glenn, M. J., Gockerman, J. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0021 · Cited by 329
Humanised monoclonal antibody therapy for rheumatoid arthritis
Isaacs, J. D., Hale, G., Cobbold, S. P., Waldmann, H., Watts, R. A., Hazleman, B. L., & Keogan, M. T. (1992) · The Lancet · doi:10.1016/0140-6736(92)92294-p · Cited by 308
Skin-resident T cells: the ups and downs of on site immunity
Clark, R. A. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.247 · Cited by 298
Self-citationInfectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders
Martin, S. I., Marty, F. M., Fiumara, K., Treon, S. P., Gribben, J. G., & Baden, L. R. (2006) · Clinical Infectious Diseases · doi:10.1086/504811 · Cited by 270
Liu, L., Zhong, Q., Tian, T., Dubin, K. A., Athale, S., & Kupper, T. S. (2010) · Nature Medicine · doi:10.1038/nm.2078 · Cited by 257
Self-citationLundin, J., Österborg, A., Brittinger, G., Crowther, D., Dombret, H., Engert, A., Epenetos, A. A., Gisselbrecht, C., Huhn, D., Jaeger, U., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3257 · Cited by 255
Oncogenomic analysis of mycosis fungoides reveals major differences with Sézary syndrome
van Doorn, R., van Kester, M. S., Dijkman, R., Vermeer, M. H., Mulder, A. A., Szuhai, K., Knijnenburg, J., Boer, J. M., Willemze, R., & Tensen, C. P. (2008) · Blood · doi:10.1182/blood-2008-04-153031 · Cited by 207
Kim, Y. H., Duvic, M. A., Obitz, E., Gniadecki, R., Iversen, L., Österborg, A., Whittaker, S. J., Illidge, T., Schwarz, T., Kaufmann, R., et al. (2007) · Blood · doi:10.1182/blood-2006-12-062877 · Cited by 204
A Novel Method for the Isolation of Skin Resident T Cells from Normal and Diseased Human Skin
Clark, R. A., Chong, B. F., Mirchandani, N., Yamanaka, K.-I., Murphy, G. F., Dowgiert, R. K., & Kupper, T. S. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700199 · Cited by 201
Self-citationBernengo, M. G., Quaglino, P., Comessatti, A., Ortoncelli, M., Novelli, M., Lisa, F., & Fierro, M. T. (2007) · Haematologica · doi:10.3324/haematol.11127 · Cited by 173
Dummer, R., HEALD, P. W., Nestle, F. O., Ludwig, E., Laine, E., Hemmi, S., & Burg, G. (1996) · Blood · doi:10.1182/blood.v88.4.1383.bloodjournal8841383 · Cited by 168
Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab
Kennedy, G., Seymour, J. F., Wolf, M., Januszewicz, H., Davison, J., McCormack, C. J., Ryan, G., & Prince, H. M. (2003) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2003.00143.x · Cited by 145
Phase II study of alemtuzumab in chronic lymphoproliferative disorders
Ferrajoli, A., O'Brien, S. M., Cortes, J. E., Giles, F. J., Thomas, D. A., Faderl, S. H., Kurzrock, R., Lerner, S. A., Kontoyiannis, D. P., & Keating, M. J. (2003) · Cancer · doi:10.1002/cncr.11551 · Cited by 127
Shin, J. J., Monti, S., Aires, D., Duvic, M. A., Golub, T. R., Jones, D. A., & Kupper, T. S. (2007) · Blood · doi:10.1182/blood-2006-12-061507 · Cited by 125
Self-citationCardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome
Lenihan, D. J., Alencar, A. J., Yang, D. J., Kurzrock, R., Keating, M. J., & Duvic, M. A. (2004) · Blood · doi:10.1182/blood-2003-07-2345 · Cited by 122
Razvi, E. S., Jiang, Z., Woda, B. A., & Welsh, R. M. (1995) · Europe PMC (PubMed Central) · Cited by 112
The Immunopemthogenesis of Cutaneous T-cell Lymphoma
Rook, A. H., & HEALD, P. W. (1995) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30054-6 · Cited by 106
Querfeld, C., Mehta, N., Rosen, S. T., Guitart, J., RADEMAKER, A. W., Gerami, P., & Kuzel, T. M. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190903216770 · Cited by 105
The Immunopathogenesis of Cutaneous T-Cell Lymphoma
Rook, A. H. (1993) · Archives of Dermatology · doi:10.1001/archderm.1993.01680250098016 · Cited by 98
Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma
Lansigan, F., & Foss, F. M. (2010) · Drugs · doi:10.2165/11532190-000000000-00000 · Cited by 97
Suchin, K. R. (2002) · Archives of Dermatology · doi:10.1001/archderm.138.9.1137 · Cited by 96
Yoo, E. K., Cassin, M., Lessin, S. R., & Rook, A. H. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.116345 · Cited by 81
Siders, W., Shields, J. D., Garron, C., Hu, Y., Boutin, P., Shankara, S., Weber, W. D., Roberts, B., & Kaplan, J. M. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428191003777963 · Cited by 77
Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
Hale, G., & Waldmann, H. (1996) · PubMed · Cited by 70
High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma
Clark, R. A., Shackelton, J. B., Watanabe, R., Calarese, A. W., Yamanaka, K.-I., Campbell, J. J., Teague, J. E., Kuo, H. P., Hijnen, D., & Kupper, T. S. (2010) · Blood · doi:10.1182/blood-2010-05-287664 · Cited by 62
Self-citationRider, D. A., Havenith, C. E. G., de Ridder, R., Schuurman, J., Favre, C., Cooper, J. C., Walker, S. A., Baadsgaard, O., Marschner, S., vandeWinkel, J. G. J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1148 · Cited by 50
Tendler, C. L., Burton, J. D., Jaffe, J. S., Danielpour, D., Charley, M. R., McCoy, J. P., Pittelkow, M. R., & Waldmann, T. A. (1994) · PubMed · Cited by 46
Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly
Alinari, L., Geskin, L. J., Grady, T., Baiocchi, R. A., Bechtel, M. A., & Porcu, P. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.11.009 · Cited by 38
Successful treatment of chemotherapy‐refractory Sézary syndrome with alemtuzumab (Campath‐1H)
Gautschi, O. P., Blumenthal, N., Streit, M., Solenthaler, M., Hunziker, T., & Zenhäusern, R. (2003) · European Journal Of Haematology · doi:10.1046/j.0902-4441.2004.00169.x · Cited by 34
Jones, J., & Coles, A. J. (2009) · PubMed · Cited by 31
Ferenczi, K., Yawalkar, N., Jones, D. A., & Kupper, T. S. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.7.909 · Cited by 30
Self-citationNosari, A., Tedeschi, A., Ricci, F., & Montillo, M. (2008) · Haematologica · doi:10.3324/haematol.12465 · Cited by 18
Roch, N., Salameire, D., Gressin, R., Morand, P., Épaulard, O., Pavèse, P., Brion, J., & Stahl, J. ‐. (2008) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540701684817 · Cited by 16
Capalbo, S. F., Delia, M., Dargenio, M., Liso, A., Diomede, D., Garofalo, L., & Liso, V. (2003) · Medical Oncology · doi:10.1385/mo:20:4:389 · Cited by 16
Gibbs, S. D., Herbert, K. E., McCormack, C. J., Seymour, J. F., & Prince, H. M. (2004) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2004.00332.x · Cited by 14
Principles of Cytotoxic T Lymphocyte Induction and Recognition
Whitton, J. L., & Zhang, J. (1995) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-79657-9_16 · Cited by 10
Alemtuzumab in Sézary syndrome: efficient but not innocent.
Üre, Ü., Ar, M. C., Salihoğlu, A., Güner, Ş. İ., Baran, A., Oğuz, O., & Ferhanoğlu, B. (2007) · PubMed · doi:10.1684/ejd.2007.0269 · Cited by 10
Chan, H. E. H., Jilani, I. B., Chang, R., & Albitar, M. X. (2007) · Methods in molecular biology · doi:10.1007/978-1-59745-323-3_11 · Cited by 4
Cited by
Sorted by citations
Human T cell development, localization, and function throughout life
Kumar, B. V., Connors, T. J., & Farber, D. L. (2018) · Immunity · doi:10.1016/j.immuni.2018.01.007 · Cited by 1,257
Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61769-3 · Cited by 1,205
Coles, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61768-1 · Cited by 1,198
Tissue-resident memory T cells: local specialists in immune defence
Mueller, S. N., & Mackay, L. K. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.3 · Cited by 1,006
Human memory T cells: generation, compartmentalization and homeostasis
Farber, D. L., Yudanin, N. A., & Restifo, N. P. (2014) · Nature Reviews Immunology · doi:10.1038/nri3567 · Cited by 897
Metadata
- Authors
- Clark, R. A., Watanabe, R., Teague, J. E., Schlapbach, C., Tawa, M. C., Adams, N., Dorosario, A. A., Chaney, K. S., Cutler, C. S., LeBoeuf, N. R., Carter, J. B., Fisher, D. C., & Kupper, T. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Dana-Farber Brigham Cancer Center (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Clark, Rachael A.
- Watanabe, Rei
- Kupper, Thomas S.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2012-01-18
- Volume
- 4
- Issue
- 117
- Pages
- 117ra7-117ra7
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC3373186
- OpenAlex
- W2076870975
- Cited by
- 367
- References
- 53
- Citations by year
- 2026: 6 · 2025: 17 · 2024: 17 · 2023: 18 · 2022: 25 · 2021: 38 · 2020: 27 · 2019: 27 · 2018: 33 · 2017: 26 · 2016: 31 · 2015: 37 · 2014: 25 · 2013: 20 · 2012: 19
- FWCI
- 40.39
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- U.S. Public Health Service (R01 A1025082)
- National Cancer Institute (P50 CA9368305, P50CA093683)
- National Institute of Allergy and Infectious Diseases (R37AI025082, R01AI097128)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR056720, R01AR065807)
- Topics
- Health Sciences › Medicine › Dermatology › Cutaneous lymphoproliferative disorders research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Keywords
- cutaneous T-cell lymphoma, alemtuzumab, central memory T cells, effector memory T cells, mycosis fungoides, T cell recirculation, skin-homing T cells, neutrophils, IL-4, interferon-gamma, infection susceptibility, T cell depletion
- MeSH terms
- CD52 Antigen, Alemtuzumab, Aged, Aged, 80 and over, Antigens, Neoplasm, Antineoplastic Agents, Female, Glycoproteins, Humans, Immune System, Immunologic Memory, Male, Middle Aged, Mycosis Fungoides, Neutrophils, Phenotype, Skin, T-Lymphocytes, T-Lymphocytes, Cytotoxic, Antigens, CD, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
